CTOR Citius Oncology Inc. Final Profit

Corporate emblem and logo of Citius Oncology (CTOR)

Citius Oncology, Inc. (CTOR) focuses on assisting bladder cancer patients, generating revenue through insurance reimbursements for immunotherapy and the implementation of methods to reduce treatment toxicity. The business is also developing the launch of a treatment for cutaneous T-cell lymphoma, which is currently in the clinical planning stage. The current metric is -0.05. This price chart reflects the profit dynamics of the organization.

CTOR (Citius Oncology, Inc.) Net Profit history from 08/14/2024 to 10/31/2026

Analytical breakdowns and data insights for company Citius Oncology (CTOR)

- stock value and consensus price forecast:
Market Price Citius Oncology Inc|CTOR - Price Target Chart
- market capitalization data:
Market Value Citius Oncology Inc|CTOR - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Citius Oncology|CTOR - Book Capitalization|Market Cap to Net Assets Ratio citiusonc.com|CTOR - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Citius Oncology, Inc.|CTOR - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Citius Oncology Inc.|CTOR - Company Aggregate Debts|Debts to Book Value Citius Oncology Inc|CTOR - Company Long-Term Debts|Company Current Liabilities Citius Oncology|Interim Coverage Ratio citiusonc.com
- net income and valuation multiples indicators:
CTOR - Net Income
Fundamental valuation:CTOR Citius Oncology Inc
Manufactured product of Citius Oncology Inc.

Capital protection amid volatility requires objective data rather than market interpretations. In the aggressive oncology drug sector, where success depends on commercialization rates, financial stability becomes the primary criterion for survival. This indicator captures the daily total of all operations, measuring the net cash result of each transaction. By analyzing the operating results of Citius Oncology, Inc. (CTOR), an investor sees the real profit dynamics without market dogmas. A break in this trend signals critical risks for the portfolio.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Net Income sellaslifesciences.com SLS|Net Profit ACTU (Actuate Therapeutics)|Net Financial Result TuHURA Biosciences Inc. (HURA)|TARA: Net Income|Fate Pharma - Profit After Payment of Taxes|WHWK: Net Profit|TCRX - Net Financial Result|Net Income CSBR|Net Profit XBiotech USA|Company Net Income CEL-SCI Corporation (CVM)|Net Financial Result OS Therapies, Inc.|Radiopharm Theranostics Limited - Net Income|Final Profit ARTV|ANL - Company Net Income|Company Net Income Veru Inc|Tempest Tx (TPST) - Company Net Income|Company Profit XLO|RENB (Renovaro Biosciences) - Net Profit|Net Income Mural Bio (MURA)|Company Net Income Kairos Pharma Ltd (KAPA)|OKUR - Company Net Income|Company Net Income CytoMed Therapeutics Limited GDTC|Curis Inc. - Company Net Income|APLM - Company Net Income|Company Net Income tharimmune.com|ADVB: Net Profit|Annual Net Income Genprex Inc. GNPX|Net Income CLDI|Company Net Income Sunshine Biopharma Inc. SBFM|Net Income XBIO (Xenetic Biosciences)|SLRX (salariuspharma.com) - Final Profit|Net Profit PPBT (Purple Biotech Ltd.)|Net Financial Result American Oncology Network Inc (AONC)|BGNE - Company Net Income|CKPT (Checkpoint Therapeutics Inc) - Company Profit|ELEV: Net Profit|Net Income iCAD|Net Income IKNA|Notable Labs Ltd (NTBL) - Net Financial Result|Net Profit VIRX|Net Income MorphoSys Corporation MOR|NAYA Biosciences - Net Income|Profit After Payment of Taxes AAPGV (ascentage.com)